Article in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Ana Luisa Teixeira de AlmeidaLaboratory of Viral Morphology and Morphogenesis, Oswaldo Cruz Institute, Oswaldo Cruz Foundation-Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil.ORCID 0000-0002-2189-7115
Andréa Marques Vieira da SilvaLaboratory of Immunological Technology, Department of Experimental and Preclinical Development, Bio-Manguinhos, Oswaldo Cruz Foundation-Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil.ORCID 0000-0003-4566-2545
Mariana Mello E SouzaLaboratory of Preclinical Trials, Department of Experimental and Preclinical Development, Bio-Manguinhos, Oswaldo Cruz Foundation-Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil.ORCID 0009-0000-8409-6350
Miguel Pires Medeiros Diniz RodriguesLaboratory of Immunological Technology, Department of Experimental and Preclinical Development, Bio-Manguinhos, Oswaldo Cruz Foundation-Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil.ORCID 0009-0003-5018-723X
Felipe Soares CoelhoLaboratory of Immunological Technology, Department of Experimental and Preclinical Development, Bio-Manguinhos, Oswaldo Cruz Foundation-Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil.ORCID 0000-0002-4533-1896
Lorenna Carvalho da RosaLaboratory of Immunological Technology, Department of Experimental and Preclinical Development, Bio-Manguinhos, Oswaldo Cruz Foundation-Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil.ORCID 0000-0002-1236-523X
Tamiris AzamorLaboratory of Immunological Technology, Department of Experimental and Preclinical Development, Bio-Manguinhos, Oswaldo Cruz Foundation-Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil.ORCID 0000-0002-4047-2091
Carolina Baeta Salvador VáradyLaboratory of Preclinical Trials, Department of Experimental and Preclinical Development, Bio-Manguinhos, Oswaldo Cruz Foundation-Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil.ORCID 0000-0003-3883-7714
Bruno Jorge Duque da SilvaLaboratory of Preclinical Trials, Department of Experimental and Preclinical Development, Bio-Manguinhos, Oswaldo Cruz Foundation-Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil.ORCID 0000-0002-5986-4642
Alex Costa de AlmeidaLaboratory of Preclinical Trials, Department of Experimental and Preclinical Development, Bio-Manguinhos, Oswaldo Cruz Foundation-Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil.
Renata Tourinho SantosLaboratory of Virological Technology, Department of Experimental and Preclinical Development, Bio-Manguinhos, Oswaldo Cruz Foundation-Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil.
Rodrigo MüllerLaboratory of Preclinical Trials, Department of Experimental and Preclinical Development, Bio-Manguinhos, Oswaldo Cruz Foundation-Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil.
Rafael Braga GonçalvesDepartment of Biochemistry, Biomedical Institute, Federal University of the State of Rio de Janeiro, Rio de Janeiro 20211-040, RJ, Brazil.ORCID 0000-0002-0117-0787
Ana Paula Dinis Ano BomLaboratory of Immunological Technology, Department of Experimental and Preclinical Development, Bio-Manguinhos, Oswaldo Cruz Foundation-Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil.
Debora Ferreira Barreto-VieiraLaboratory of Viral Morphology and Morphogenesis, Oswaldo Cruz Institute, Oswaldo Cruz Foundation-Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil.ORCID 0000-0003-1014-0755
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has revealed a complex interplay between respiratory and neurological manifestations. This study utilized K18-hACE2 transgenic mice to investigate the morphological, ultrastructural, and transcriptomic changes induced by SARS-CoV-2 infection in both lungs and brain tissues. Histopathological analysis at seven days post-infection revealed significant pulmonary damage characterized by interstitial pneumonia, alveolar septal thickening, with a marked inflammatory infiltrate predominantly consisting of neutrophils and lymphocytes, and an abnormal profile of type II pneumocytes. Concurrently, in the brain, we observed vasculitis, gliosis, and edema, indicating an inflammatory response and vascular compromise that can disturb the blood-brain barrier. In addition, gene expression in lung tissue presented increased
Indexed as
gene expressionhistopathologyK18-hACE2 miceSARS-CoV-2transmission electron microscopy
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
SARS-CoV-2 Effects on Respiratory and Neurological Systems: Morphological Findings and Gene Expression in K18-hACE2 Mice Model. · full record | OpenQuestion